Home / Hexarelin 2MG 5MG 10MG
  • Hexarelin  2MG 5MG 10MG
  • Hexarelin  2MG 5MG 10MG
  • Hexarelin  2MG 5MG 10MG

Hexarelin 2MG 5MG 10MG

This product is supplied as Research Use Only (RUO) material for scientific research purposes.
Hexarelin is a synthetic growth hormone-releasing peptide (GHRP) widely studied in endocrine research and peptide science. Research on Hexarelin focuses on growth hormone signaling pathways, receptor interactions, and mechanisms involved in hormonal regulation. Its unique peptide structure makes it an important compound for researchers investigating growth-related biological processes and peptide-receptor activity. The 3mg specification is suitable for laboratory studies, analytical evaluation, and molecular research applications.
$120
$150
Quantity
ADD TO CART
BUY IT NOW
  • Detail

    Research Peptide · For Laboratory Use Only

    Hexarelin (Examorelin) 5mg

    Growth Hormone Secretagogue · GHRP-6 Analog Hexapeptide · Lyophilized Powder · Purity ≥98% (HPLC)

    Hexarelin, also known by its international nonproprietary name Examorelin (development codes EP-23905 and MF-6003), is a synthetic hexapeptide growth hormone secretagogue (GHS) and a highly selective agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a). Its sequence — His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ — was derived from the GHRP-6 analog research lineage, with the key modification of replacing D-Trp by 2-methyl-D-Trp to improve potency and metabolic stability.

    Hexarelin is one of the most thoroughly studied members of the GHRP family: in clinical research it proved to be a potent, dose-dependent stimulator of growth hormone release — and remarkably, one of the few GH-releasing peptides active after oral and intranasal administration. It reached Phase II clinical trials for growth hormone deficiency and congestive heart failure before development was discontinued. Each vial is supplied as a sterile lyophilized (freeze-dried) powder to ensure maximum stability.

    Product Specifications

    Product Name Hexarelin (Examorelin)
    CAS Number 140703-51-1 (free base)
    Amino Acid Sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ (synthetic hexapeptide derived from GHRP-6, with 2-methyl-D-Trp substituted at position 2 and a C-terminal amide)
    Molecular Formula C₄₇H₅₈N₁₂O₆
    Molecular Weight 887.04 g/mol (free base)
    Receptor Profile Highly selective GHS-R1a (ghrelin / growth hormone secretagogue receptor) agonist
    Quantity 5mg per vial
    Physical Form White to off-white lyophilized powder
    Purity ≥99% as determined by HPLC
    Storage -20°C for long term; 2–8°C for short term (lyophilized)

    What is Hexarelin?

    The discovery of ghrelin — the stomach-derived natural ligand of the growth hormone secretagogue receptor — transformed the study of growth hormone regulation. Before ghrelin was even identified, medicinal chemists had already built a family of synthetic receptor agonists that mimicked its GH-releasing action: the growth hormone-releasing peptides (GHRPs). Hexarelin was developed by Mediolanum Farmaceutici as one of the most advanced members of this family.

    Hexarelin was engineered from the GHRP-6 template to deliver stronger and more durable GH release. Its key structural features include:

    • 2-methyl-D-Trp replacing the D-Trp of GHRP-6, enhancing receptor affinity and resistance to enzymatic degradation;
    • A hexapeptide backbone (His–D-2-methyl-Trp–Ala–Trp–D-Phe–Lys) conserved across the GHRP pharmacophore;
    • A C-terminal amide (Lys-NH₂), stabilizing the peptide against carboxypeptidase cleavage.

    In published research, Hexarelin has been investigated in a wide range of settings, including:

    • Growth hormone physiology — Hexarelin releases more GH than GHRH in humans and shows striking synergy when combined with GHRH; it reached Phase II clinical trials for growth hormone deficiency;
    • Pediatric growth research — intranasal Hexarelin was studied in short children as a non-injectable GH-releasing approach;
    • Cardiovascular research — Hexarelin has demonstrated cardioprotective effects in ischemia-reperfusion, myocardial infarction and cardiac fibrosis models, mediated through GHS-R1a and the CD36 receptor;
    • Congestive heart failure — Hexarelin advanced to Phase II trials in CHF patients before development was discontinued;
    • Aging and body composition studies, where GH secretagogues serve as tools to explore the somatotropic (GH/IGF-1) axis.

    With a clinical history spanning GH deficiency, short stature and heart failure research — plus an exceptional feature of oral and intranasal activity — Hexarelin remains one of the best-characterized research tools for studying the ghrelin receptor and the growth hormone axis.

    Mechanism of Action

    1. GHS-R1a (Ghrelin Receptor) Agonism

    Hexarelin binds and activates the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor activated by the natural hormone ghrelin. Receptors are located in the pituitary gland and hypothalamus, where their activation drives pulsatile GH secretion.

    2. Dual Pituitary–Hypothalamic Action

    Unlike GHRH, which acts only at the pituitary, Hexarelin acts at both levels: it directly stimulates pituitary somatotrophs and, in parallel, antagonizes hypothalamic somatostatin tone — the physiological "brake" on GH release — producing a robust, pulse-like GH response.

    3. Synergy with GHRH

    In human studies, Hexarelin combined with GHRH produced massive increases in plasma GH levels even at low doses — far exceeding the effect of either compound alone. This synergy makes the pair a classical research combination in GH physiology studies.

    4. Cardioprotective Signaling (GHS-R1a / CD36)

    Beyond GH release, Hexarelin binds the CD36 scavenger receptor in cardiac tissue. In animal models it has been shown to reduce cardiomyocyte apoptosis, limit ischemia-reperfusion injury and attenuate fibrosis — the basis of its development history in heart failure research.

    5. Broader Endocrine Profile

    Like other GHRPs, Hexarelin mildly stimulates prolactin, ACTH and cortisol release, without affecting glucose, LH, FSH or TSH levels. Long-term studies report a partial, reversible desensitization of the GH response — an important characteristic for research protocol design.

    Handling & Storage Guidelines

    • Lyophilized powder: Store at -20°C for long-term stability; 2–8°C is acceptable for short-term storage. Avoid repeated temperature cycling and protect from light and moisture.
    • Before opening: Allow the vial to reach room temperature and briefly centrifuge to ensure the full contents collect at the bottom of the vial.
    • Reconstitution: Add bacteriostatic water or an appropriate solvent gently along the vial wall. Swirl slowly until fully dissolved; avoid vigorous shaking. Peptides are fragile molecules — gentle handling preserves structural integrity.
    • Reconstituted solution: Store at 2–8°C and use promptly; do not refreeze the solution.
    • General: Handle with standard laboratory protective equipment (gloves, lab coat, eye protection).

    Why Choose Our Hexarelin?

    🧪

    Verified Purity

    Each batch tested by HPLC & MS; COA available upon request.

    📦

    Secure Packaging

    Sealed vials with temperature-protective packaging for safe delivery.

    🚚

    Fast Dispatch

    Orders processed promptly with tracking provided.

    Frequently Asked Questions

    Q1: Is Hexarelin the same as Examorelin?

    A: Yes. Hexarelin is the original research name; Examorelin is the same molecule's international nonproprietary name (INN). It was also known under the development codes EP-23905 and MF-6003.

    Q2: How does Hexarelin differ from GHRP-6 and GHRP-2?

    A: All three belong to the GHRP family and act through the same ghrelin receptor (GHS-R1a). Hexarelin was derived from the GHRP-6 sequence, with 2-methyl-D-Trp substituted at position 2 — a modification reported to make it a more potent and longer-acting GH releaser than GHRP-6. GHRP-2 (pralmorelin) is a closely related hexapeptide with a different substitution pattern; hexarelin's development history is distinguished by its oral/intranasal activity and cardiovascular research program.

    Q3: How does Hexarelin differ from Ipamorelin or CJC-1295?

    A: The mechanisms differ. Hexarelin is a GH secretagogue (ghrelin receptor agonist), while CJC-1295 is a GHRH analog acting through the GHRH receptor — the two pathways are complementary and often studied together. Ipamorelin is also a secretagogue, but is noted for its selectivity (minimal prolactin/ACTH/cortisol stimulation), whereas Hexarelin is characterized by stronger GH-releasing potency with mild co-release of prolactin and cortisol.

    Q4: How should I store it after receiving?

    A: Keep unopened vials at -20°C for long-term storage. Once reconstituted, refrigerate at 2–8°C and use promptly; do not refreeze the solution.

    Q5: Is a Certificate of Analysis (COA) available?

    A: Yes, third-party tested COA documentation can be provided for each batch. Please contact our customer service with your order number.

    ⚠ Research Use Only — Disclaimer

    All product information provided on this page is solely for information dissemination and educational purposes. The products offered are intended exclusively for in vitro laboratory research and are not pharmaceuticals. They have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for the purposes sold here, and must not be used to prevent, treat or cure any medical condition, disease or ailment.

    It is strictly prohibited to introduce these products into the human or animal body in any form. By purchasing, the buyer acknowledges full responsibility for the proper handling, use and compliance with all applicable local laws and regulations.

  • Customer Reviews
    No comments